SBMFF OTC
Sino Biopharmaceutical Limited
1W: +0.0%
1M: -5.8%
3M: +17.2%
YTD: -20.3%
1Y: -36.2%
3Y: +111.9%
5Y: -9.8%
$0.69
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$31.0B
+7.4% ▲
5Y CAGR: +5.6%
Gross Profit
$25.5B
+8.2% ▲
5Y CAGR: +6.6%
Operating Income
$6.6B
+8.2% ▲
5Y CAGR: +9.6%
Net Income
$2.3B
-34.8% ▼
5Y CAGR: -3.8%
EPS (Diluted)
$0.13
-31.6% ▼
5Y CAGR: -2.8%
EBITDA
$7.8B
+27.5% ▲
5Y CAGR: +6.6%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $26.9B | $26.0B | $26.2B | $28.9B | $31.0B |
| YoY Growth | +13.6% | -3.1% | +0.7% | +10.2% | +7.4% |
| Cost of Revenue | $5.3B | $5.8B | $5.0B | $5.3B | $5.6B |
| Gross Profit | $21.5B | $21.5B | $21.2B | $23.5B | $25.5B |
| Gross Margin | 80.1% | 82.8% | 81.0% | 81.5% | 82.1% |
| R&D Expenses | $3.7B | $4.3B | $4.5B | $5.2B | $5.7B |
| SG&A Expenses | $12.7B | $12.6B | $11.1B | $12.2B | $13.1B |
| Operating Expenses | $17.2B | $16.0B | $15.5B | $17.4B | $18.8B |
| Operating Income | $5.1B | $5.6B | $5.8B | $6.1B | $6.6B |
| Operating Margin | 18.9% | 21.5% | 22.1% | 21.3% | 21.4% |
| Interest Expense | $309M | $429M | $495M | $295M | $271M |
| Income Before Tax | $18.6B | $5.2B | $5.4B | $5.3B | $6.8B |
| Tax Expense | $2.0B | $697M | $797M | $493M | $1.6B |
| Net Income | $14.6B | $2.5B | $2.3B | $3.5B | $2.3B |
| Net Margin | 54.4% | 9.8% | 8.9% | 12.1% | 7.4% |
| EPS (Diluted) | $0.73 | $0.12 | $0.10 | $0.19 | $0.13 |
| EBITDA | $19.9B | $6.7B | $7.0B | $6.1B | $7.8B |
| Shares Outstanding | 19.28B | 19.02B | 18.53B | 18.30B | 18.06B |